NEW YORK, Nov. 11 (GenomeWeb News) - Orchid Biosciences reported a slight drop in revenues for the quarter ended Sept. 30, accompanied by shrinking R&D expenses and net losses.

The company's total quarterly revenues of $11.8 million were down from its third-quarter 2002 revenues of $13.3 million, which included $886,000 in revenues from the Life Sciences product business it sold in December 2002.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.